Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is a well-positioned, financially stable company with a strong potential for growth in the transplant testing market. With their diverse product portfolio, recent strategic acquisitions, and positive industry developments, the company is poised for success in the coming years. Additionally, their close collaboration with CMS and focus on innovation solidify their position as a leader in the precision medicine space, making them a promising investment opportunity.

Bears say

CareDx is facing headwinds due to Medicare limiting coverage for its kidney and heart surveillance tests, which we believe will continue to put pressure on the company's core transplant business. Additionally, their new AlloHeme product, while targeting a potentially large market, has not yet established its reimbursement and price, adding uncertainty to future revenue streams. Finally, competition in the precision medicine space for transplant patients is increasing, and CareDx may struggle to maintain its dominant market share and drive revenue growth.

CareDx (CDNA) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 3 analysts, CareDx (CDNA) has a Buy consensus rating as of Aug 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.